A new House bill would amend the Food, Drug, and Cosmetic Act to grant FDA more authority against products that don't meet the definition of dietary supplement.
The latest of what will be several guidance documents on the NDI process provides updates on the agency’s proposed method to handle proprietary information.
The product license allows finished products to be marketed with claims relevant to liver, cardiovascular, and gut health, as well as blood glucose and stress.